币界网报道:Bitcoin investment company Parataxis Holdings LLC announced that it has reached a final investment agreement of 25 billion won with Bridge Biotherapeutics, Inc., which enables it to acquire a controlling stake in the latter. After the transaction is completed, Bridge Biotherapeutics will be renamed Parataxis Korea and continue to be listed on the Korean startup market KOSDAQ. The company expects to announce more details about the transaction after the shareholders' meeting in August. Earlier news, Parataxis Holdings LLC plans to go public through a merger with special purpose acquisition company SilverBox Corp IV, and the two parties have signed a non-binding letter of intent.